Antimicrobial treatment of "complicated" intra-abdominal infections and the new IDSA guidelines - A commentary and an alternative european approach according to clinical definitions

European Journal of Medical Research

Volumn 16, Issue 3, 2011, Pages 115-126

  Eckmann, Christian ^a   Dryden, M ^b   Montravers, P ^c   Kozlov, R ^d   Sganga, G ^e  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Royal Hampshire Hospital   (United Kingdom)

^c BICHAT HOSPITAL   (France)

^d SMOLENSK STATE MEDICAL UNIVERSITY   (Russian Federation)

^e CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPENICILLIN; AMPHOTERICIN B; ANIDULAFUNGIN; BETA LACTAMASE INHIBITOR; CARBAPENEM; CASPOFUNGIN; CEFEPIME; CEFTRIAXONE; CEPHALOSPORIN; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; COLISTIN; DAPTOMYCIN; DORIPENEM; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; FLUCONAZOLE; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; MEROPENEM; METRONIDAZOLE; MICAFUNGIN; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE; VANCOMYCIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE; ECHINOCANDIN; IMIPENEM; VORICONAZOLE;

ABDOMINAL INFECTION; ACINETOBACTER; ACUTE HEMORRHAGIC PANCREATITIS; ANASTOMOSIS LEAKAGE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; APPENDIX PERFORATION; ASPIRATION BIOPSY; BACTERIAL COUNT; BACTERIAL PERITONITIS; BACTEROIDES FRAGILIS; BILIARY TRACT SURGERY; CANDIDA; CANDIDIASIS; CHOLANGITIS; CLOSTRIDIUM DIFFICILE INFECTION; COLITIS; COLON CARCINOMA; COMMUNITY ACQUIRED DIFFUSE PERITONITIS; COMMUNITY ACQUIRED INFECTION; COMMUNITY ACQUIRED LOCALIZED PERITONITIS; COMPLICATED INTRAABDOMINAL INFECTION; COMPUTER ASSISTED TOMOGRAPHY; DIGESTIVE SYSTEM PERFORATION; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG SAFETY; ENTEROCOCCACEAE; ESCHERICHIA COLI; GASTROINTESTINAL SURGERY; HAEMOPHILUS INFLUENZAE; HUMAN; ILEOTRANSVERSOSTOMY; INFECTED NECROSIS; INFECTION; INFECTION RISK; KLEBSIELLA; LIVER CIRRHOSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; MYCOSIS; NECROSIS; NOSOCOMIAL POST INTERVENTIONAL DIFFUSE PERITONITIS; NOSOCOMIAL POSTOPERATIVE DIFFUSE PERITONITIS; NOSOCOMIAL POSTTRAUMATIC DIFFUSE PERITONITIS; NOTE; PERITONITIS; POSTOPERATIVE INFECTION; PRACTICE GUIDELINE; PROTEUS; SECONDARY INFECTION; STAPHYLOCOCCUS AUREUS; TREATMENT INDICATION; TREATMENT PLANNING; VALVULAR HEART DISEASE; VANCOMYCIN RESISTANT ENTEROCOCCUS; ABDOMINAL ABSCESS; ANTIMICROBIAL THERAPY; APACHE; COMPLICATED ABDOMINAL INFECTION; DISEASE SEVERITY; EMERGENCY WARD; ENTEROCOCCUS; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; HEALTHCARE ASSOCIATED INFECTION; MORTALITY RATE; PERSONAL EXPERIENCE; POSTOPERATIVE COMPLICATION; PREVALENCE; PSEUDOMONAS; REVIEW;

ANTI-INFECTIVE AGENTS; EUROPE; EVIDENCE-BASED MEDICINE; HUMANS; PERITONITIS; PRACTICE GUIDELINES AS TOPIC;

EID: 79954514875     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (69)

1. Solomkin JS, Mazuski JE, Bradley JS et al. Diagnosis and management of complicated intra-abdominal infections in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Inf Dis 2010;50:133-64
2. Weigelt JA. Empiric treatment options in the management of complicated intra-abdominal infections. Cleve Clin J Med 2007;74(suppl 4):S29-37
3. Augustin P, Kermarrec N, Muller-Serieys C, Montravers P. Risk factors for multi-drug resistant bacteria and optimization of empirical antibiotic therapy in postoperative peritonitis. Crit Care 2010;14:R20
4. Bader F, Schroeder M, Kujath P, Muhl E, Bruch HP, Eckmann C. Diffuse prostoperative peritonitis:value of diagnostic parameters and impact of early indication for relaparotomy. Eur J Med Res 2009;14:1-6
5. Boucher HW, Talbot GH, Bradley JS et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Inf Dis 2009;48:1-12
6. Itani KMF, Dryden MS, Bhattacharyya H, Kunkel MJ et al. Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus. Am J Surg 2010;
7. Arbeit RD, Maki D et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Inf Dis 2004; 38: 1673-1681 (Pubitemid 38781657)
8. Babincak T, Ellis-Grosse E, Dartois N et al. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections. Clin INf Dis 2005;41:354-67
9. Birmingham MC, Rayner CR, Meagher AM et al. Linezolid in the treatment of multidrug-resistant, Gram-positive infections: experience from a compassionate-use program. Clin Inf Dis 2003;36:159-68
10. Swoboda S, Ober M, Hainer C et al. Tigecycline for the treatment of patients with severe sepsis or septic shock: a drug evaluation in a surgical intensive care unit. J Antimicrob Chemother 2008;61:729-33 (Pubitemid 351321153)
11. Bassetti M, Nicolini L, Repetto E, Rghi E, Del Bono V, Viscoli C. Tigecycline use in serious nosocomial infections: a drug use evaluation. BMC Infect Dis 2010;10:287
12. Eckmann C, Heizmann WR, von Eiff C, Leitner E, Löschmann PA, Bodmann KF. Prospective, non-interventional multicentre trial of tigecycline in the treatment of severely ill patients. Chemother J 2010;19:165-166
13. http://www.fda.gov/Drugs/DrugSafety/ucm224370.htm (last visit Jan 15th 2011)
14. Dryden M. Complicated skin and soft tissue infection. J Antimicrob Chemother. 2010;65 (S3):iii35-44
15. Wilcox MH. The tide of antimicrobial resistance and selection. Int J Antimicrob Agents 2009; 34 S3: S6-10.
16. Nathwani D. New antibiotics for the management of complicated skin and soft tissue infections: are they any better? Int J Antimicrob Agents 2009; 34: S24-9.
17. Eckmann C, Dryden M. Treatment of complicated skin and soft-tissue infections caused by resistant bacteria: value of linezolid, tigecycline, daptomycin and vancomycin. Eur J Med Res 2010;15:554-563
18. Kumar A, Roberts D, Wood KE et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34: 1589-1596 (Pubitemid 43810035)
19. Kumar A, Ellis P, Arabi Y et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 2009;136:1237-48
20. Engel C, Brunkhorst FM, Bone HG et al. Epidemiology of sepsis in Germany: results from a national prospective multicenter study. Intensive Care Med 2007; 33: 606-618 (Pubitemid 46474888)
21. Wong PF, Gilliam AD, Kumar S et al. Antibiotic regimens for secondary peritonitis of gastrointestinal origin in adults. Cochrane Database Syst Rev 2005; 18: CD004539
22. Edelsberg J, Berger A, Schell S et al. Economic consequences of failure of initial antibiotic therapy in hospitalized adults with complicated intra-abdominal infections. Surg Infect 2008; 9: 335-347 (Pubitemid 351873405)
23. Barie P. The cost of failure. Surg Infect 2008; 9: 313-315 (Pubitemid 351873417)
24. Davey PG, Marwick C. Appropriate versus inappropriate antimicrobial therapy. Clin Microbiol Infect 2008; 14S3: S15-S21
25. Oxford Centre of Evidence-based Medicine: levels of evidence (march 2009) http://www.cebm.net/index.aspx?o=1025 (last visit: Jan 15th 2011)
26. Ebell MH, Siwek J, Weiss BD et al. Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. J Am Board Fam Pract 2004;17:59-67
27. Monneuse O, Tissot E, Gruner L et al. Diagnosis and treatment of spontaneous group A streptococcal peritonitis. Br J Surg. 2010;97:104-8
28. Rimola A, Garcia-Tsao G, Navasa M et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. J Hepatol 2000; 32: 142-153
29. Javid G, Khan BA, Khan BA et al. Short course ceftriax-one therapy in spontaneous bacterial peritonitis. Postgrad Med J 1998;74:592-599
30. Mowat C, Stanley AJ. Spontaneous bacterial peritonitis - diagnosis, treatment and prevention. Aliment Pharmacol Ther 2001; 15: 1851-1859 (Pubitemid 34014339)
31. Sort P, Navasa M, Arroyo V et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Eng J Med 1999; 341: 403-409 (Pubitemid 29362513)
32. Stuart S, Booth TC, Cash CJ et al. Complications of continuous ambulatory peritoneal dialysis. Radiographics 2009; 29: 441-460
33. Lima RC, Barreira A, Cardoso FL et al. Ciprofloxacin and cefazolin as a combination for empirical initial therapy of peritoneal dialysis-related peritonitis: five-year follow-up. Perit Dial Int 2007; 27: 56-60 (Pubitemid 46403284)
34. Van Ruler O, Mahler CW, Boer KR et al. Comparison of on-demand vs planned relaparotomy strategy in patients with severe peritonitis: a randomized trial. JAMA 2007; 298:865-872
35. Bodmann KF, Grabein B et al. Recommendations of the Paul-Ehrlich-society for chemotherapy for the empirical antimicrobial treatment of severe infections of adults. Eckmann C, Isenmann R, Kujath P et al.: Intra-abdominal infections. Chemother J 2010;19:217-222
36. Dupont H. The empiric treatment of nosocomial intraabdominal infections. Int J Infect Dis 2007; 11(S1): S1-S6 (Pubitemid 46977798)
37. Harbarth S, Uckay I. Are there any patients with peritonitis who require empiric therapy for enterococcus? Eur J Microbiol Infect Dis 2004; 23: 73-77
38. Paul M, Silbiger I, Grozinsky S et al. Beta lactam antibiotic monotherapy versus lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev 2006; 25: CD003344
39. Masterton RG, Galloway A, French G et al. Guidelines for the management of hospital-acquired pneumonia in the UK. J Anticrob Chemother 2008; 62: 5-34
40. Giske CG, Monnet DL, Cars O et al. Clinical and economic impact of common multidrug-resistant Gram-negative bacilli. Antimicrob Agents Chemother 2008; 52: 813-821 (Pubitemid 351358357)
41. Chromik AM, Meiser A, Hölling J et al. Identification of patients at risk for development of tertiary peritonitis on a surgical intensive care unit. J Gastrointest Surg 2009; 13: 1358-1367
42. Mazuski JE. Antimicrobial treatment for intraabdominal infections. Expert Opin Pharmacother 2007; 8: 2933-2945
43. Krepel CJ, Gohr CM, Edmiston CE, Condon RE. Surgical sepsis: constancy of antibiotic susceptibility of causative organisms. Surgery 1995; 117: 505-509
44. De Waele JJ, Hoste EA, Blot SI. Blood stream infections of abdominal origin in the intensive care unit: characteristics and determinants of death. Surg Infect 2008; 9: 171-177
45. Roehrborn A., Thomas L, Potreck O et al. The microbiology of postoperative peritonitis. Clin Infect Dis 2001; 33: 1513-1519
46. Nickols RL, Muzik AC. Enterococcal infections in surgical patients: the mystery continues. Clin Infect Dis 1992; 15:72-76
47. Halle E, Padberg J, Rosseau S et al. Linezolid-resistant Enterococcus faecium and Enterococcus faecalis isolated from a septic patient: report of first isolates in Germany. Infection 2004; 32: 182-183 (Pubitemid 38757026)
48. Livermore DM. Beta-lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995; 8: 557-584
49. Lehner S, Grabein B, Pfaller P, Kopp R. Relevance of ESBL-producing pathogens for clinical surgery: diagnostics, therapy and prevention. Chirurg 2009; 80: 527-536
50. DiNubile MJ, Friedland I, Chan CY et al. Bowel colonization with resistant Gram-negative bacilli after antimicrobial therapy of intra-abdominal infections. Eur J Microbiol Infect Dis 2005; 24: 443-449
51. Sotto A, Lefrant JY, Fabbro-Peray P et al. Evaluation of antimicrobial therapy management of 120 consecutive patients with secondary peritonitis. J Antimicrob Chemother 2002; 50: 569-572
52. Driscoll JA, Brody SL, Kollef MH. The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections. Drugs 2007; 67: 351-368 (Pubitemid 46425550)
53. Montravers P, Dupont H, Gauzit R et al. Candida as a risk factor for mortality in peritonitis. Crit Care Med 2006; 34: 646-652
54. Blot SI, Vandewoude KH, De Waele JJ. Candida peritonitis. Curr Opin Crit Care 2007; 13: 195-199
55. Blot S, Dimopoulos G, Rello J, Vogelaers D. Is Candida really a threat in the ICU? Curr Opin Crit Care 2008; 14: 600-604
56. Leon C, Ruiz-Santana S, Saavedra P et al. A bedside scoring system ("Candida score") for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med 2006; 34: 730-737
57. PeLz RK, Hendrix CW, Swoboda SM et al. Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann Surg 2001;233:542-548 (Pubitemid 32234953)
58. Eggimann P, Francioli P, Bille J et al. Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit Care Med 1999; 27:1066-1072 (Pubitemid 29314312)
59. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007; 20: 133-163 (Pubitemid 46167771)
60. Pappas PG, Kauffman CA, Andes D et al. Clinical practise guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-535
61. Whitcomb DC. Acute pancreatitis. N Eng J Med 2006; 354: 2142-2150 (Pubitemid 43736614)
62. Banks PA, Gerzov SG, Langevin RE et al. CT-guided aspiration of suspected pancreatic infection: bacteriology and clinical outcome. Int J Pancreatol 1995; 18: 265-270 (Pubitemid 26023509)
63. Besselink MG, Verwer TJ, Schoenmakers EJ et al. Timing of surgical intervention in necrotizing pancreatitis. Arch Surg 2007; 142: 1194-1201 (Pubitemid 350294273)
64. Bassi C, Larvin M, Villatore E. Antibiotic therapy for prophylaxis against infection of pancreatic necrosis in acute pancreatitis. Cochrane Database Syst Rev 2003;(4): CD002941
65. Villatore E, Bassi C, Larvin M. Antibiotic therapy for prophylaxis against infection of pancreatic necrosis in acute pancreatitis. Cochrane Database Syst Rev 2006;(4): CD002941
66. Mazaki T, Ishii Y, Takayama T. Meta-analysis of prophylactic use in acute necrotizing pancreatitis. Br J Surg 2006; 93: 674-684 (Pubitemid 43886018)
67. Nathans AB, Curtis JR, Beale RJ et al. Management of the critically ill patient with severe acute pancreatitis. Crit Care Med 2004; 32: 2524-2436
68. De Waele JJ. A role for prophylactic antibiotics in necrotizing pancreatitis? Crit Care 2008; 12: 195
69. Gerding DN, Johnson S. Management of Clostridium difficile infection: thinking inside and outside the box. Clin Infect Dis 2010;51:1306-1313